Exacerbation of infliximab-induced palmoplantar psoriasis under ustekinumab therapy in a patient with ankylosing spondylitis

Journal of Clinical Rheumatology

Volumn 17, Issue 7, 2011, Pages 385-386

  Safa, Gilles ^a   Martin, Antoine ^a   Darrieux, Laure ^a  

^a Centre Hospitalier de Saint Brieuc   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; ETANERCEPT; ETRETIN; INFLIXIMAB; LEUKOCYTE ANTIGEN; LEUKOCYTE ANTIGEN B27; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG; USTEKINUMAB; VITAMIN D DERIVATIVE;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX SCORE; CASE REPORT; CLINICAL ASSESSMENT TOOL; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; JOINT STIFFNESS; LOW BACK PAIN; PARAKERATOSIS; PRIORITY JOURNAL; PUSTULOSIS PALMOPLANTARIS; SACROILIITIS;

ACUTE DISEASE; ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; METHOTREXATE; PSORIASIS; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT FAILURE;

EID: 80053371455     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0b013e31823262c3     Document Type: Article

References (17)

1. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther. 2008;117:244-279.
2. Sfikakis PP, Iliopoulos A, Elezoglou A, et al. Psoriasis induced by anti-tumor necrosis factor therapy: A paradoxical adverse reaction. Arthritis Rheum. 2005;52:2513-2518.
3. Kary S, Worm M, Audring H, et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis. 2006;65:405-407.
4. de Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-> inhibitors in patients with rheumatologic conditions. Arch Dermatol. 2007;143:223-231.
5. Palucka AK, Blanck JP, Bennett L, et al. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A. 2005;102:3372-3377.
6. Cuchacovich R, Espinoza CG, Virk Z, et al. Biologic therapy (TNF-alpha antagonists)Yinduced psoriasis: A cytokine imbalance between TNF-alpha and IFN-alpha? J ClinRheumatol. 2008;14:353-356.
7. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from randomised, double-blind, placebo-controlled trial (PHOENIX1). Lancet. 2008;371:1665-1674.
8. Papp KA, Langley RG, Lebwohl L, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis : 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX2). Lancet. 2008;371:1675-1684.
9. Gerdes S, Franke J, Domm S, et al. Ustekinumab in the treatment of palmo-plantar pustulosis. Br J Dermatol. 2010;163:1116-1118.
10. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633-640.
11. Necas M, Vasku V. Ustekinumab in the treatment of severe rupioid psoriasis: A case report. Acta Dermatovenerol Alp Panonica Adriat. 2010;19:23-27.
12. Gregoriou S, Kazakos C, Christofidou E, et al. Pustular psoriasis development after initial ustekinumab administration in chronic plaque psoriasis. Eur J Dermatol. 2011;21:104-105.
13. Wenk KS, Claros JM, Ehrlich A. Flare of pustular psoriasis after initiating ustekinumab therapy [published online ahead of print]. J Dermatol Treat. 2011.
14. Reddy M, Torres G, McCormick T, et al. Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters. J Dermatol. 2010;37:413-425.
15. Garcia-Valladares I, Cuchacovich R, Espinoza LR. Comparative assessment of biologics in treatment of psoriasis: Drug design and clinical effectiveness of ustekinumab. Drug Des Dev Ther. 2011;5:41-49.
16. Wang X, Lin Z, Wei Q, et al. Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis. Rheumatol Int. 2009;29:1343-1347.
17. Mei Y, Pan F, Gao J, et al. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol. 2011;30:269-273.